title: [Acne vulgaris].
abstract: Acne vulgaris is worldwide the most common skin disease. Acne is an inflammatory disorder in whose emergence androgens, PPAR ligands, the IGF-1 signaling pathway, regulating neuropeptides and environmental factors are probably involved. These factors interrupt the natural cycling process in the sebaceous gland follicle and support the transition of microcomedones to comedones and inflammatory lesions. Proinflammatory lipids and cytokines are mediators for the development of acne lesions. Bacterial antigens can potentate the inflammatory phenomena. Acne is predominantly treated with combination therapy. Selecting a treatment regimen depends on the exact classification of acne type and severity. The development of scars is the main criterion for the choice of systemic therapy. Retinoids for mild comedonal acne and the combination of retinoids with antibiotics and/or benzoyl peroxide for mild to moderate papulopustular acne are the drugs of first choice for topical treatment. The use of topical antibiotics is not recommended any more because of the development of resistant bacterial strains. Systemic antibiotics, in combination with topical retinoids and/or benzoyl peroxide, for moderate papular/nodular acne and isotretinoin for severe nodular/conglobate acne are the columns of systemic acne treatment. Systemic anti-androgens are used in women against moderate papulopustular acne. Due to advances in the understanding of the underlying inflammatory mechanisms in recent years the development of new therapeutic agents with good efficacy and better side effect profile should be expected in the future.
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie/Immunologisches Zentrum, Städtisches Klinikum Dessau, Auenweg 38, 06847, Dessau, Deutschland, christos.zouboulis@klinikum-dessau.de.
authors.forename: C C
authors.initials: CC
authors.lastname: Zouboulis
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis* / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D012176:Retinoids / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D012176:Retinoids
references.citation: J Drugs Dermatol. 2013 Oct;12(10):1104-9
references.pmid: 24085045
references.citation: Exp Dermatol. 2005 Feb;14(2):143-52
references.pmid: 15679586
references.citation: Hautarzt. 2013 Apr;64(4):235-40
references.pmid: 23532504
references.citation: Lancet. 2012 Jan 28;379(9813):361-72
references.pmid: 21880356
references.citation: Clin Dermatol. 2004 Sep-Oct;22(5):360-6
references.pmid: 15556719
references.citation: Exp Dermatol. 2009 Oct;18(10):821-32
references.pmid: 19555434
references.citation: J Dtsch Dermatol Ges. 2010 Feb;8(2):105-14
references.pmid: 20151947
references.citation: Dtsch Arztebl Int. 2014 Apr 25;111(17):301-12
references.pmid: 24828100
references.citation: J Eur Acad Dermatol Venereol. 2012 Feb;26 Suppl 1:1-29
references.pmid: 22356611
references.citation: J Eur Acad Dermatol Venereol. 2014 May;28(5):527-32
references.pmid: 24134468